A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2018
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 19 Mar 2018 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 12 Dec 2017 Preliminary results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 13 Jul 2017 Planned number of patients changed from 78 to 160.